SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
About this item
Full title
Author / Creator
BLAZE-1 Investigators , Chen, Peter , Nirula, Ajay , Heller, Barry , Gottlieb, Robert L , Boscia, Joseph , Morris, Jason , Huhn, Gregory , Cardona, Jose , Mocherla, Bharat , Stosor, Valentina , Shawa, Imad , Adams, Andrew C , Van Naarden, Jacob , Custer, Kenneth L , Shen, Lei , Durante, Michael , Oakley, Gerard , Schade, Andrew E , Sabo, Janelle , Patel, Dipak R , Klekotka, Paul and Skovronsky, Daniel M
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In a phase 2 trial, outpatients with Covid-19 who received a single infusion of a 2800-mg dose of the neutralizing antibody LY-CoV555 had a greater reduction from baseline in viral load than those who received placebo. Hospitalization was less frequent among antibody-treated patients (1.6% vs. 6.3%).
Alternative Titles
Full title
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Authors, Artists and Contributors
Author / Creator
Chen, Peter
Nirula, Ajay
Heller, Barry
Gottlieb, Robert L
Boscia, Joseph
Morris, Jason
Huhn, Gregory
Cardona, Jose
Mocherla, Bharat
Stosor, Valentina
Shawa, Imad
Adams, Andrew C
Van Naarden, Jacob
Custer, Kenneth L
Shen, Lei
Durante, Michael
Oakley, Gerard
Schade, Andrew E
Sabo, Janelle
Patel, Dipak R
Klekotka, Paul
Skovronsky, Daniel M
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7646625
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7646625
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2029849
